Suven Life Sciences Share Price Today (SUVEN)
TODAY IN ONE LINE
SUVEN fell 1.4% on light volume, lagging Nifty's 0.8% move, supported by recent strong earnings.
With a market cap of ₹8,208.85 Cr., it trades at a P/E of -30.15. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Suven Life Sciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 70.2% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.03x
- ●Promoter BuyingPromoters increased holdings by 2.79% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Suven Life Sciences News
What changed recently?
Recent events, corporate actions, and announcements.
Suven Life Sciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Suven Life Sciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Suven Life Sciences Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Suven Life Sciences Limited — derived from the live tape, not yesterday's close.
Suven Life Sciences Limited last traded at ₹311.7 with an intraday range of ₹310.2–₹319.85 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹311.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 336.93 | +25.23 | +8.10% |
| R3 | 327.28 | +15.58 | +5.00% |
| R2 | 323.57 | +11.87 | +3.81% |
| R1 | 317.63 | +5.93 | +1.90% |
| PIVOT | 313.92 | 2.22 | 0.71% |
| CURRENT | 311.70 | — | — |
| S1 | 307.98 | -3.72 | -1.19% |
| S2 | 304.27 | -7.43 | -2.38% |
| S3 | 298.33 | -13.37 | -4.29% |
| S4 | 288.68 | -23.02 | -7.38% |
SUVEN is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹315.45–₹319.85
Trading Inside opening range
Suven Life Sciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Suven Life Sciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Suven Life Sciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹8,208.85 Cr. and reported EPS of ₹-12.14.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 7 | 7 ▲ 6.9% |
| Sales Growth YoY %Derived | -43.08% | 6.89% |
| Other Income | 11 | 14 ▲ 27.8% |
| Total Income | 18 | 21 ▲ 19.9% |
| — | — | |
| Gross ProfitDerived | 7 | 7 ▲ 6.9% |
| Gross Margin %Derived | 100.00% | 100.00% |
| 172 | 292 ▲ 69.1% | |
| EBITDA (Operating Profit)Derived | -166 | -285 ▼ 71.6% |
| OPM %Derived | -2,490.66% | -3,998.80% |
| 6 | 6 ▼ 1.7% | |
| Profit Before Tax (PBT) | -161 | -276 ▼ 71.9% |
| — | — | |
| Effective Tax %Derived | — | — |
| Total Profit for Period | -161 | -276 ▼ 71.9% |
| Net Profit (Owner's PAT)Derived | -161 | -276 ▼ 71.9% |
| Net Profit Margin %Derived | -2,415.11% | -3,884.13% |
| PAT Growth YoY %Derived | -52.98% | -71.91% |
| Earnings Per Share (EPS ₹) | -7.37 | -10.48 ▼ 42.2% |
| Diluted Shares Outstanding (Cr) | 22 | 26 ▲ 20.9% |
| Other Comprehensive Income (Net of Tax) | -1 | -1 ▼ 103.0% |
| Total Expenses (incl. D&A & Interest) | 178 | 297 ▲ 66.8% |
| Material Cost % of RevenueDerived | — | — |
| Employee Cost % of RevenueDerived | 312.88% | 339.43% |
| Other Cost % of RevenueDerived | 2,277.78% | 3,759.37% |
| Interest Coverage (x)Derived | -3,682.30x | -1,838.51x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 625 | 664 ▲ 6.1% | 14 ▼ 97.8% | 13 ▼ 6.5% | 12 ▼ 12.1% | 14 ▲ 14.3% | 12 ▼ 13.6% | 7 ▼ 43.1% | 7 ▲ 6.9% | |
| Sales Growth YoY %Derived | — | 6.12% | -97.83% | -6.50% | -12.12% | 14.31% | -13.64% | -43.08% | 6.89% | |
| Other Income | 23 | 24 ▲ 4.1% | 14 ▼ 42.1% | 8 ▼ 44.8% | 5 ▼ 31.4% | 8 ▲ 58.9% | 21 ▲ 150.1% | 11 ▼ 48.4% | 14 ▲ 27.8% | |
| Total Income | 649 | 688 ▲ 6.0% | 28 ▼ 95.9% | 21 ▼ 25.4% | 17 ▼ 19.2% | 22 ▲ 28.1% | 33 ▲ 49.3% | 18 ▼ 46.5% | 21 ▲ 19.9% | |
154 | 174 ▲ 12.9% | — ▼ 100.0% | — | — | — | — | — | — | ||
| Gross ProfitDerived | 472 | 490 ▲ 3.9% | 14 ▼ 97.1% | 13 ▼ 6.5% | 12 ▼ 12.1% | 14 ▲ 14.3% | 12 ▼ 13.6% | 7 ▼ 43.1% | 7 ▲ 6.9% | |
| Gross Margin %Derived | 75.42% | 73.85% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | |
273 | 330 ▲ 20.6% | 130 ▼ 60.5% | 94 ▼ 28.1% | 134 ▲ 43.5% | 139 ▲ 3.9% | 140 ▲ 0.2% | 172 ▲ 23.4% | 292 ▲ 69.1% | ||
| EBITDA (Operating Profit)Derived | 198 | 160 ▼ 19.1% | -116 ▼ 172.1% | -80 ▲ 30.8% | -122 ▼ 52.9% | -126 ▼ 2.9% | -128 ▼ 1.7% | -166 ▼ 29.5% | -285 ▼ 71.6% | |
| OPM %Derived | 31.70% | 24.18% | -802.77% | -594.04% | -1,033.31% | -929.78% | -1,094.72% | -2,490.66% | -3,998.80% | |
26 | 26 ▼ 0.1% | 5 ▼ 81.8% | 5 ▲ 9.4% | 5 ▼ 4.6% | 13 ▲ 160.6% | 14 ▲ 10.0% | 6 ▼ 58.4% | 6 ▼ 1.7% | ||
| Profit Before Tax (PBT) | 196 | 159 ▼ 18.8% | -106 ▼ 167.0% | -77 ▲ 27.2% | -122 ▼ 57.5% | -118 ▲ 3.1% | -106 ▲ 10.3% | -161 ▼ 51.5% | -276 ▼ 71.9% | |
72 | 72 ▼ 0.1% | -12 ▼ 117.0% | -5 ▲ 56.3% | — ▲ 100.0% | — | -1 | — ▲ 100.0% | — | ||
| Effective Tax %Derived | 36.74% | 45.23% | 11.45% | 6.87% | — | — | 0.94% | — | — | |
| Total Profit for Period | 124 | 87 ▼ 29.7% | -94 ▼ 208.4% | -72 ▲ 23.4% | -122 ▼ 69.1% | -118 ▲ 3.1% | -105 ▲ 11.2% | -161 ▼ 53.0% | -276 ▼ 71.9% | |
| Net Profit (Owner's PAT)Derived | 124 | 87 ▼ 29.7% | -94 ▼ 208.4% | -72 ▲ 23.4% | -122 ▼ 69.1% | -118 ▲ 3.1% | -105 ▲ 11.2% | -161 ▼ 53.0% | -276 ▼ 71.9% | |
| Net Profit Margin %Derived | 19.78% | 13.10% | -653.62% | -535.31% | -1,029.99% | -873.52% | -898.63% | -2,415.11% | -3,884.13% | |
| PAT Growth YoY %Derived | — | -29.71% | -208.37% | 23.42% | -69.08% | 3.06% | 11.15% | -52.98% | -71.91% | |
| Earnings Per Share (EPS ₹) | 6.48 | 4.55 ▼ 29.8% | -4.93 ▼ 208.4% | -3.78 ▲ 23.3% | -5.59 ▼ 47.9% | -5.42 ▲ 3.0% | -4.82 ▲ 11.1% | -7.37 ▼ 52.9% | -10.48 ▼ 42.2% | |
| Diluted Shares Outstanding (Cr) | 19 | 19 ▲ 0.0% | 19 ▲ 0.0% | 19 ▲ 0.0% | 22 ▲ 14.2% | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 26 ▲ 20.9% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 50.3% | -0 ▼ 114.5% | -0 ▼ 3.8% | -0 ▲ 50.9% | 0 ▲ 226.2% | -0 ▼ 131.6% | -1 ▼ 872.2% | -1 ▼ 103.0% | |
| Total Expenses (incl. D&A & Interest) | 453 | 529 ▲ 16.8% | 135 ▼ 74.5% | 99 ▼ 26.8% | 139 ▲ 41.0% | 140 ▲ 0.8% | 139 ▼ 1.0% | 178 ▲ 28.4% | 297 ▲ 66.8% | |
| Material Cost % of RevenueDerived | 27.97% | 30.77% | — | — | — | — | — | — | — | |
| Employee Cost % of RevenueDerived | 9.80% | 9.97% | 120.77% | 137.46% | 177.48% | 137.53% | 162.38% | 312.88% | 339.43% | |
| Other Cost % of RevenueDerived | 33.92% | 39.70% | 782.00% | 556.58% | 955.84% | 892.24% | 1,032.34% | 2,277.78% | 3,759.37% | |
| Interest Coverage (x)Derived | 38.22x | 36.64x | -217.42x | -103.52x | -239.17x | -458.07x | -849.16x | -3,682.30x | -1,838.51x |
Suven Life Sciences segment analysis : revenue and profit mix.
Disclosed business segments at Suven Life Sciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Suven Life Sciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Suven Life Sciences Limited.
Our AI distills the core fundamental drivers supporting Suven Life Sciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Suven Life Sciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding of 70.15% signals insider confidence and long-term commitment.
Zero total debt provides financial flexibility for R&D investments and operations.
Latest quarterly sales grew 85.20% YoY, indicating revenue turnaround momentum.
Phase III Masupirdine trial for Alzheimer's offers significant pipeline potential.
Minimal leverage with debt-to-equity ratio of 0.0282 reflects financial stability.
Key Risks.
Operating margin of -4077.70% reflects severe losses and unsustainable operations.
ROE of -78.80% and ROCE of -87.00% indicate severe capital inefficiency.
Operating cash flow negative at -69.6 Cr, burning cash unsustainably.
No dividend yield offered, providing no income stream to shareholders.
Price-to-book ratio of 13.23x significantly overvalued versus peer benchmarks.
Flip Conditions.
Fundamental risk. a shrinking deal pipeline (TCV) or margins below historical averages would weaken the thesis.
Watch wage inflation and attrition rates — primary threats to operating leverage in IT.
Suven Life Sciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Suven Life Sciences Limited is highlighted for quick read-across.
Quick Compare
Suven Life Sciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Suven Life Sciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Suven Life Sciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Suven Life Sciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Suven Life Sciences Limited stood at 35.6% of traded volume, against a 20-day average of 32.7%.
Suven Life Sciences announcements: results, concalls, ratings, M&A.
Filings Suven Life Sciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Suven Life Sciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 82 documents below.
Copy of Newspaper Publication
Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Suven Life Sciences Limited has informed the Exchange about Schedule of meet
Press Release
Suven Life Sciences Limited has informed the Exchange regarding a press release dated July 10, 2026, titled "Suven Life Sciences to Present Five…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Suven Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
General Updates
Suven Life Sciences Limited has informed the Exchange about revised outcome of Board Meeting - Incorporation of Wholly owned Subsidiary (WOS) in…
Investor decks & rating reports.
Suven Life Sciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Suven Life Sciences has declared, sequenced by announce and record date.
Suven Life Sciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Suven Life Sciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Suven Life Sciences as reported to SEBI — buying and selling signals from the people who know the business best.
Suven Life Sciences insider activity below tracks 3 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Jasti Property and Equity Holdings Private Limited | Insider | 06 Mar 2026 | buy | +3.18 Cr | ₹425.7 Cr. | ₹134.00 |
| Jasti Property and Equity Holdings Private Limited | Insider | 06 Mar 2026 | buy | +3.18 Cr | ₹425.7 Cr. | ₹134.00 |
| Jasti Property and Equity Holdings Private Limited | Insider | 06 Mar 2026 | buy | +3.18 Cr | ₹425.7 Cr. | ₹134.00 |
About Suven Life Sciences Limited: business, sector, key facts.
What Suven Life Sciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Suven Life Sciences Limited operates in the Healthcare Research Analytics & Technology industry under the Healthcare sector, listed as NSE: SUVEN, BSE: 530239.
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company concentrating on the research, development, and commercialization of novel therapeutics to treat neurodegenerative disorders. Their operations span across India, the United States, Europe, and other international markets. The company's core business is focused on drug discovery and development, specifically targeting new chemical entities to combat central nervous system (CNS) diseases.
Suven's pipeline includes several promising product candidates at various stages of development. Masupirdine (SUVN-502) is being investigated for Alzheimer's disease and associated neuropsychiatric symptoms. Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist, is being explored for the treatment of sleep and cognitive disorders. Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist, is in development for depressive disorders.
Further enriching their portfolio, Suven is actively developing Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist aimed at treating cognitive disorders. Additionally, the company has several other compounds under investigation, including SUVN-I6107 and SUVN-M8036, targeting cognitive and psychiatric disorders respectively. SUVN-D1044 is being developed for gastrointestinal disorders, showcasing the company's exploration beyond the CNS therapeutic area.
Established in 1989 and headquartered in Hyderabad, India, Suven Life Sciences Limited has undergone a name change from Suven Pharmaceuticals Pvt. Ltd. in 2003. The company's history reflects a commitment to innovation in the field of neurodegenerative disease treatment. Currently, it operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Indegene (INDGN) Share PricePeer
- Syngene International (SYNGENE) Share PricePeer
- Vimta Labs (VIMTALABS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Suven Life Sciences Limited (SUVEN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Suven Life Sciences Limited (SUVEN)?
The current share price of Suven Life Sciences Limited (SUVEN) is ₹311.7. Today, the stock has declined by ₹4.30 (1.36%), trading in a range of ₹310.2 to ₹319.85. The stock opened at ₹319 with a trading volume of 3,17,418 shares.
02Is Suven Life Sciences Limited stock a good investment for long-term?
Suven Life Sciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹8,208.85 crores, P/E ratio of -30.15, ROE of -78.80%, and ROCE of -87.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Suven Life Sciences Limited stock?
The 52-week high price of Suven Life Sciences Limited (SUVEN) is ₹371, while the 52-week low is ₹124.11. Currently trading at ₹311.7, the stock is 76.0% away from its 52-week low and 16.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Suven Life Sciences Limited stock at the current price?
Whether to buy Suven Life Sciences Limited stock at ₹311.7 depends on multiple factors. The stock is currently trading with a P/E ratio of -30.15 and P/B ratio of 14.09. Today's performance shows a loss of 1.36%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Suven Life Sciences Limited and when is the next dividend?
Suven Life Sciences Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹311.7, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Suven Life Sciences Limited?
Suven Life Sciences Limited's key financial metrics include: P/E Ratio: -30.15, P/B Ratio: 14.09, ROE: -78.80%, ROCE: -87.00%, Dividend Yield: 0.00%, EPS: ₹-12.14, Book Value: ₹26.2, and Debt-to-Equity: 2.82. The company's market cap stands at ₹8,208.85 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Suven Life Sciences Limited stock performing today in the market?
Suven Life Sciences Limited stock opened at ₹319 and is currently trading at ₹311.7, showing a decline of ₹4.30 (1.36%). The intraday high is ₹319.85 and low is ₹310.2. The trading volume stands at 3,17,418 shares, indicating moderate market participation today.
08What is the P/E ratio of Suven Life Sciences Limited and what does it indicate?
Suven Life Sciences Limited has a Price-to-Earnings (P/E) ratio of -30.15, which means investors are willing to pay ₹-30.15 for every ₹1 of earnings. With an EPS of ₹-12.14, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Suven Life Sciences Limited (SUVEN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.